摘要
目的:观察国产吉西他滨(泽菲)联合重组人血管内皮抑制素(恩度)二线治疗晚期胰腺癌的近期疗效及毒性反应。方法:15例患者均经病理学或影像学确诊为胰腺癌,全组病例均采用泽菲联合恩度治疗:泽菲1000mg/m2,静滴30分钟,每周1次,连用2周;恩度7.5mg/m2,一般为15mg/次,加入生理盐水500ml中缓慢静脉滴注,滴注时间为3~4小时,第1~14天连续给药。每3周重复。结果:15例患者中,可评价疗效患者14例,无CR病例,PR1例,SD4例,PD9例,疾病控制率35.7%(5/14)。临床受益反应率40.0%(6/15)。主要毒副反应为骨髓抑制,恶心呕吐以及心电图异常。结论:泽菲联合恩度方案治疗晚期胰腺癌疗效较好,毒副反应轻,耐受性良好,值得进一步研究。
Objective:To observe the short-time effect and toxic reaction of domestic gemcitabine plus endostar in the second line of treatment of patients with advanced pancreatic cancer. Methods:Fifteen histologically or cytologically confirmed advanced pancreatic cancer patients were treated with domestic gemcitabine plus endostar (domestic gemcitabine 1 000mg/m^2 on day 1 and day 8, 15mg endostar solved in 500ml of normal saline was slow intravenously dropped from day 1 to day 14) every 3 weeks. Results:Among 15 patients, 14 were evaluated with 35.7% disease control rate( DCR), 1 case have got PR,4 SD,9 PD. Clinical beneficial rate(CBR) was 40.0%. The main toxicities were marrow restraint, gastrointestinal reaction and electrocardiogram dysfunction. Conclusion: The domestic gemcitabine plus endostar in the second line of treatment of patients with advanced pancreatic cancer has a good short-time effects, slight advere reaction and patients tolerate well, it is worth studying further.
出处
《临床肿瘤学杂志》
CAS
2008年第12期1132-1134,共3页
Chinese Clinical Oncology
关键词
胰腺肿瘤
重组人血管内皮抑制素
吉西他滨
化学治疗
Advanced pancreatic cancer
Recombinant human endostatin
Gemcitabine
Chemotherapy